HONG KONG, Nov. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for first-line treatment of triple-negative breast cancer (TNBC) has been granted Breakthrough...
Hence then, the article about akeso s ivonescimab secures fourth breakthrough therapy designation in china for first line treatment of triple negative breast cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer )
Also on site :
- Disney and TikTok Shop Team Up To Bring Holiday Magic in First-Ever Super Brand Day
- Psychologists Say This Common 3-Word Phrase Can Accidentally Shut Down a Conversation (Hint: It’s Not ‘That Doesn’t Work’)
- Gloria Trevi Is HEAT Latin Music Awards’ Artista Oro, Celebrating ‘Everything She Has Achieved & Everything That’s Yet to Come’